36X.F ASCENTAGE PHARM. DL-0001

Healthcare Biotechnology Frankfurt Exchange
3.22 EUR
Close of Nov 11, 2026
0.8450 7.40
Market cap
EUR 1.20B
P/E
-
P/B
16.99x
ROE
-93.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 36X.F undervalued?

Graham number

The Graham number of ASCENTAGE PHARM. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ASCENTAGE PHARM. DL-0001 fundamental analysis

No fundamental analysis for ASCENTAGE PHARM. DL-0001 yet.

ASCENTAGE PHARM. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ASCENTAGE PHARM. DL-0001

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecul…

Full company profile